Boston Scientific (BSX) Q1 2026 earnings review
Q1 Beat Overshadowed by Massive Guidance Downgrade
Boston Scientific technically beat its Q1 guidance, delivering 9.4% organic revenue growth and $0.80 in adjusted EPS. However, the true story of this quarter is a drastic, unexplained cut to full-year expectations. After consistently promising 'double-digit' growth and delivering mid-teens organic growth throughout 2025, management slashed FY26 organic growth guidance from 10.0-11.0% to just 6.5-8.0%. This breaks the multi-year high-growth narrative. With Q2 organic growth guided to a midpoint of 6.0%, the company is facing a sharp, multi-quarter deceleration. Despite blockbuster clinical trial successes for WATCHMAN and FARAPULSE, the near-term financial trajectory has shifted from accelerating momentum to defensive contraction.
🐂 Bull Case
The CHAMPION-AF and ADVENT trial results are monumental. Proving WATCHMAN FLX as a superior first-line option for stroke risk reduction and FARAPULSE's four-year superiority over thermal ablation solidifies BSX's long-term competitive moat in high-growth markets.
Q1 organic growth of 9.4% beat the 8.5-10.0% guidance midpoint. The company has a track record of setting conservative guidance and beating it, suggesting the new FY26 outlook may be thoroughly de-risked.
🐻 Bear Case
A ~300 basis point cut to annual organic growth guidance just three months into the year is highly concerning. The trajectory is steeply decelerating from 18.2% a year ago to an implied 6.0% next quarter.
Despite higher revenues, adjusted operating margin fell from 28.9% in Q1 2025 to 28.0% in Q1 2026. If top-line growth is slowing, the company's ability to drive its promised 50-100 bps of annual margin expansion is severely compromised.
⚖️ Verdict: 🔴
Bearish. Management stated they delivered 'solid results,' but a 30% reduction in the annual growth rate forecast contradicts any positive spin. The market prices BSX as a high-growth medtech compounder; mid-single-digit forward guidance does not support that premium.
Key Themes
The FY26 Guidance Shock
The most critical data point in the release is the revision of FY26 guidance. Just last quarter, management projected FY26 organic growth of 10.0-11.0% and Adjusted EPS of $3.43-$3.49. That outlook has been abruptly slashed to 6.5-8.0% organic growth and $3.34-$3.41 EPS. This implies a sudden, severe deterioration in underlying market conditions, competitive dynamics, or capacity constraints that management previously denied.
Adjusted Operating Margin Compresses
Management's long-range plan banked on 50+ bps of annual operating margin expansion. In Q1 2026, Adjusted Operating Expenses grew 11.4% YoY (to $2.209B), outpacing organic revenue growth. As a result, Adjusted Operating Margin compressed by ~90 basis points, dropping from 28.9% in 25Q1 to 28.0% in 26Q1. Without the Q1 call transcript, it is unclear if this is due to FX, integration costs from recent M&A, or loss of operating leverage.
Blockbuster Clinical Data Unlocks TAM
Innovation remains the brightest spot. The CHAMPION-AF trial successfully proved WATCHMAN FLX is superior to oral anticoagulants for bleeding risk while maintaining similar efficacy. This effectively transitions the device from a second-line option to a first-line therapy, potentially expanding the addressable patient population from ~5 million to 20 million globally. Concurrently, the ADVENT trial demonstrated strong four-year superiority for FARAPULSE Pulsed Field Ablation over thermal ablation.
EMEA Region Stalling
Decelerating. The EMEA region continues to drag on performance. Operational growth in EMEA was an anemic 1.2% in Q1 2026, compared to 10.9% in the U.S. and 12.0% in APAC. In Q3 2025, management blamed EMEA weakness on the ACURATE valve discontinuation and a temporary ERP backorder. The persistence of this near-zero growth rate into 2026 suggests deeper structural or competitive issues in the European market.
Neuromodulation Momentum
Accelerating. Neuromodulation was the fastest-growing division on a percentage basis, posting 15.4% organic growth to reach $318M. This validates the company's aggressive M&A strategy in the pain space, including the recent integration of Nalu Medical and the just-completed acquisition of Valencia Technologies (eCoin System), which expands their footprint into urge urinary incontinence.
Significant Foreign Exchange Headwinds
The macro environment continues to pressure the top line. The company reported a 2.2% negative impact from foreign currency fluctuations in Q1 2026 (11.6% reported growth vs 9.4% operational). If the U.S. dollar remains strong, this will continue to artificially depress reported earnings throughout the year.
Other KPIs
Decelerating. Organic growth came in at 11.2%. While this is solid double-digit performance, it marks a steep decline from the hyper-growth seen in early 2025 (Q1 2025 organic growth was 25.6%). As FARAPULSE and WATCHMAN penetrate the market and face tougher YoY comparables, the segment's ability to carry the entire company's growth rate is diminishing.
Stable. Organic growth was 5.7%, up slightly from 5.3% in Q1 2025. Endoscopy grew 6.8% organically, while Urology lagged at 0.5% organic growth. Urology continues to be a weak spot, requiring execution turnaround despite the new Asurys fluid management system clearance.
Guidance
Decelerating. A sharp drop from Q1's 9.4% and less than half of the 17.4% organic growth achieved in Q2 2025. This implies near-term headwinds are intensifying, completely contradicting the 'solid results' PR narrative.
Accelerating sequentially from Q1's $0.80, but the midpoint ($0.83) represents roughly 10% YoY growth compared to Q2 2025 ($0.75). This trails the mid-teens EPS growth the company achieved throughout 2025.
Decelerating severely vs the 10.0-11.0% target issued just one quarter prior. The company has officially abandoned its goal of double-digit organic revenue growth for the year.
Reversing trajectory compared to prior guidance. Downwardly revised from the $3.43-$3.49 estimate provided in Q4 2025. This indicates that whatever is driving the revenue deceleration is also flowing through to the bottom line.
Key Questions
The Catalyst for the Guidance Cut
You beat Q1 top-line guidance, yet slashed the full-year organic growth target by roughly 300 basis points. What specific, sudden change in market dynamics or internal operations occurred between February and April to warrant such a drastic revision?
Cardiovascular Saturation vs Competition
Cardiovascular organic growth decelerated to 11.2% from the 20%+ levels seen last year. Is this purely the result of tougher comps, or are you seeing capacity constraints in EP labs and intensified competition in the PFA space as competitors launch their systems?
Margin Expansion Viability
Adjusted operating margins compressed by roughly 90 basis points year-over-year in Q1. Given the lowered revenue growth outlook for the rest of the year, is your long-term goal of 50-100 bps of annual margin expansion still mathematically achievable in 2026?
EMEA Underperformance
EMEA operational growth was only 1.2% this quarter. The ACURATE valve comp and ERP issues were cited as transient headwinds last year. Why hasn't this region recovered to normalized growth rates?